Artiva Biotherapeutics, Inc. (ARTV)
Artiva develops natural killer cell therapies for autoimmune diseases and cancers, based in San Diego, California. It last closed at $3.86 on Nov 17, down 2.53% on the day. The average 12-month price target from 2 analysts is $4.00 (+3.6% from the last close), with a high of $4.00 and a low of $4.00. In the past 30 days there were 2 dark pool prints totaling $2.2M, the largest $2.1M.
Key Stats
Fiscal 2025Not reported for this period.
From ARTV's SEC filings, latest 10-Q for the period ending Dec 31, 2025 (filed Nov 9).
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 2 analysts who set a price target on ARTV in the past 90 days. The average target is $4.00, with a high of $4.00 and a low of $4.00, compared with the last close of $3.86.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 29 | Jefferies | Downgrade | Hold | $4 |
| Oct 27 | Wedbush | Downgrade | Hold | $4 |
| Jun 8 | Needham | Reiterated | Buy | $41 |
Technical Analysis
The stock is 18% below its 20 day and 65% below its 50 day average. It is 107% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 21), oversold. The nearest support is the Pivot S1 at $3.78, and the nearest resistance the Pivot at $3.89.
| RSI (14) | 21.38 | Oversold below 30 | Oversold |
| MACD | -0.74 | Above its signal line | Bullish |
| Stochastic | 13.3 | Near the bottom of its range | Oversold |
| ADX (14) | 59.6 | Strong downtrend | |
| Williams %R | -89.1 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -65.4 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −8.1% | Change over 10 sessions | Bearish |
| ATR (14) | $0.28 | Typical daily range, 7.2% of price |
| RSI (14) | 29.87 | Oversold below 30 | Oversold |
| MACD | -1.11 | Below its signal line | Bearish |
| Stochastic | 1.2 | Near the bottom of its range | Oversold |
| ADX (14) | 31.8 | Trending down | |
| Williams %R | -99.4 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -122.5 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −62.2% | Change over 10 sessions | Bearish |
| ATR (14) | $1.27 | Typical daily range, 32.8% of price |
What happened before
See how ARTV did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90DNo whale options trades in ARTV in the last 90 days.
Dark Pool
30DARTV Institutional Ownership
Full report →- ▲62 buying vs 21 selling
- ▲Held by funds +1.0 pts
- ▲Funds holding +26
- ▼Superinvestors: 1 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 98 | 72 | +36.1% |
| In funds' top 10 | 2 | 3 | −33.3% |
| Held by funds | 83.3% | 82.3% | +1.0 pts |
| New / increased | 32 / 30 | 39 / 25 | −3.1% |
| Reduced / sold out | 15 / 6 | 2 / 7 | +133.3% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARTV is in one of them and how their past ARTV trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ARTV in an article yet. Here's the latest on the wider market.
About Artiva Biotherapeutics
Artiva is a biotechnology company based in San Diego, California, that is developing cell therapies made from natural killer cells, a type of immune cell. Its lead product candidate, AlloNK, is made from donor cells, frozen and shipped ready for use, and is designed to work alongside antibody medicines to deplete B cells. The company is testing AlloNK in clinical trials for autoimmune diseases such as rheumatoid arthritis and Sjögren's disease, and it also has programs aimed at cancers. The intended patients are people with these conditions, and the product is not yet approved for sale.
- Headquarters
- San Diego, CA


